Jonas Goßen

Jonas Goßen

Auto-generated profile, based on publicly available information

Jonas Goßen

Institute for Advanced Simulation, Jülich Supercomputing Centre, Forschungszentrum Jülich GmbH

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
JGJonas Gossen
Jonas Gossen
SASimone Albani
Simone Albani
AHAnton Hanke
Anton Hanke
BJBenjamin P. Joseph
Benjamin P. Joseph
CBCathrine Bergh
Cathrine Bergh
GRGiulia Rossetti
Giulia Rossetti
The SARS-CoV-2 coronavirus outbreak continues to spread at a rapid rate worldwide. The main protease (Mpro) is an attractive target for anti-COVID-19 agents. Unexpected difficulties have been encountered in the design of specific inhibitors. Here, by analyzing an ensemble of ∼30 000 SARS-CoV-2 Mpro conformations from crystallographic studies and molecular simulations, we show that small structural variations in the binding site dramatically impact ligand binding properties. Hence, traditional druggability indices fail to adequately discriminate between highly and poorly druggable conformations of the binding site. By performing ∼200 virtual screenings of compound libraries on selected protein structures, we redefine the protein’s druggability as the consensus chemical space arising from the multiple conformations of the binding site formed upon ligand binding. This procedure revealed a unique SARS-CoV-2 Mpro blueprint that led to a definition of a specific structure-based pharmacophore. The latter explains the poor transferability of potent SARS-CoV Mpro inhibitors to SARS-CoV-2 Mpro, despite the identical sequences of the active sites. Importantly, application of the pharmacophore predicted novel high affinity inhibitors of SARS-CoV-2 Mpro, that were validated by in vitro assays performed here and by a newly solved X-ray crystal structure. These results provide a strong basis for effective rational drug design campaigns against SARS-CoV-2 Mpro and a new computational approach to screen protein targets with malleable binding sites.

24 July 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
JGJonas Goßen
Jonas Goßen
RRRui Pedro Rr Ribeiro
Rui Pedro Rr Ribeiro
DBDirk Db Bier
Dirk Db Bier
BNBernd Neumaier
Bernd Neumaier
PCPaolo Carloni
Paolo Carloni
GRGiulia Rossetti
Giulia Rossetti
By merging structural macromolecular data with systems biology simulations and AI-based classifier of chemical space, we developed a framework to identify therapeutic agents against GPCRs with novel chemotypes other than the physiological ligands.

28 August 2025 in Computers & Chemical Engineering
Verified
Journal Article
Closed access
QGQinghe Gao
Qinghe Gao
LBLukas Schulze Balhorn
Lukas Schulze Balhorn
ALAlessandro Laera
Alessandro Laera
RMRaoul Meys
Raoul Meys
JGJonas Goßen
Jonas Goßen
ASArtur M. Schweidtmann
Artur M. Schweidtmann

2 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJonas Goßen
Jonas Goßen
RRRui Pedro Ribeiro
Rui Pedro Ribeiro
DBDirk Bier
Dirk Bier
BNBernd Neumaier
Bernd Neumaier
PCPaolo Carloni
Paolo Carloni
GRGiulia Rossetti
Giulia Rossetti
Identifying the correct chemotype of ligands targeting receptors (i.e., agonist or antagonist) is a challenge for in silico screening campaigns. Here we present an approach that identifies novel chemotype ligands by combining structural data with a random forest agonist/antagonist classifier and a signal-transduction kinetic model. As a test case, we apply this approach to identify novel antagonists of the human adenosine transmembrane receptor type 2A, an attractive target against Parkinson’s disease and cancer. The identified antagonists were tested here in a radioligand binding assay. Among those, we found a promising ligand whose chemotype differs significantly from all so-far reported antagonists, with a binding affinity of 310±23.4 nM. Thus, our protocol emerges as a powerful approach to identify promising ligand candidates with novel chemotypes while preserving antagonistic potential and affinity in the nanomolar range.

15 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJonas Gossen
Jonas Gossen
SASimone Albani
Simone Albani
AHAnton Hanke
Anton Hanke
BJBenjamin P. Joseph
Benjamin P. Joseph
CBCathrine Bergh
Cathrine Bergh
GRGiulia Rossetti
Giulia Rossetti
The SARS-CoV-2 coronavirus outbreak continues to spread at a rapid rate worldwide. The main protease (Mpro) is an attractive target for anti-COVID-19 agents. Unfortunately, unexpected difficulties have been encountered in the design of specific inhibitors. Here, by analyzing an ensemble of ~30,000 SARS-CoV-2 Mpro conformations from crystallographic studies and molecular simulations, we show that small structural variations in the binding site dramatically impact ligand binding properties. Hence, traditional druggability indices fail to adequately discriminate between highly and poorly druggable conformations of the binding site. By performing ~200 virtual screenings of compound libraries on selected protein structures, we redefine the protein’s druggability as the consensus chemical space arising from the multiple conformations of the binding site formed upon ligand binding. This procedure revealed a unique SARS-CoV-2 Mpro blueprint that led to a definition of a specific structure-based pharmacophore. The latter explains the poor transferability of potent SARS-CoV Mpro inhibitors to SARS-CoV-2 Mpro, despite the identical sequences of the active sites. Importantly, application of the pharmacophore predicted novel high affinity inhibitors of SARS-CoV-2 Mpro, that were validated by in vitro assays performed here and by a newly solved X-ray crystal structure. These results provide a strong basis for effective rational drug design campaigns against SARS-CoV-2 Mpro and a new computational approach to screen protein targets with malleable binding sites.

21 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VWVeronika Wunderle
Veronika Wunderle
TWThomas Wilhelm
Thomas Wilhelm
SBShatha Boukeileh
Shatha Boukeileh
JGJonas Goßen
Jonas Goßen
MMMichael A. Margreiter
Michael A. Margreiter
MHMichael Huber
Michael Huber
Incidents of IgE-mediated, mast cell (MC)-driven allergic diseases are constantly rising and there is an urgent need for the development of novel pharmacological MC stabilizers. Allergen/antigen (Ag)-triggered activation of MCs via crosslinking of the high-affinity receptor for IgE (FcεRI) is regulated, amongst others, by the coordinated action of various cytosolic tyrosine kinases of the SRC family, e.g. LYN and FYN, which exert positive as well as negative functions. We report that KIRA6, an inhibitor developed for the endoplasmic reticulum (ER) stress sensor IRE1α, suppresses IgE-mediated pro-inflammatory MC activation by inhibiting both LYN and FYN. KIRA6 dose-dependently and effectively attenuates Ag-stimulated early signaling (e.g. substrate tyrosine phosphorylation, Ca 2+ mobilization, and activation of MAPK pathways) as well as effector functions such as degranulation and pro-inflammatory cytokine production/secretion in murine bone marrow-derived MCs (BMMCs). Moreover, Ag-triggered bronchoconstriction in an ex vivo model of precision-cut lung slices (PCLS), and IgE-mediated stimulation of human MCs were repressed by KIRA6. To get in-depth inside into KIRA6 interaction with three MC-relevant tyrosine kinases, LYN, FYN, and KIT, and to elicit the potential of KIRA6 structure to serve as pharmacophore for the development of respective single-, dual-, or triple-specificity inhibitors, we modeled and evaluated the binding of KIRA6 on the three kinases by applying homology modeling and molecular dynamics simulations, as well as MM GBSA calculations. We found that KIRA6 has a high propensity to bind the inactive state of LYN, FYN, and KIT with comparable affinities. In conclusion, our data suggest the use of novel inhibitors based on the KIRA6 pharmacophore as effective MC stabilizers to improve treatment of pro-inflammatory diseases with MC involvement in need of effective pharmacological interventions.